Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage …
JD Bradley, R Paulus, R Komaki, G Masters… - The lancet …, 2015 - thelancet.com
Background We aimed to compare overall survival after standard-dose versus high-dose
conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to …
conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to …
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation …
…, TM Pisansky, J Martenson, R Komaki… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: To compare the local/regional control, survival, and toxicity of combined-modality
therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the …
therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the …
[HTML][HTML] Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
…, WT Sause, RB Livingston, R Komaki… - … England Journal of …, 1999 - Mass Medical Soc
Background For small-cell lung cancer confined to one hemithorax (limited small-cell lung
cancer), thoracic radiotherapy improves survival, but the best ways of integrating …
cancer), thoracic radiotherapy improves survival, but the best ways of integrating …
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
…, LS Carpenter, K De Jaeger, R Komaki… - The lancet …, 2015 - thelancet.com
Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC)
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer
JA Roth, F Fossella, R Komaki, MB Ryan… - JNCI: Journal of the …, 1994 - academic.oup.com
Background: Patients with resectable stage IIIA non-small-cell lung cancer have a low
survival rate following standard surgical treatment. Nonrandomized trials in which induction …
survival rate following standard surgical treatment. Nonrandomized trials in which induction …
Sequential vs concurrent chemoradiation for stage III non–small cell lung cancer: randomized phase III trial RTOG 9410
…, R Paulus, CJ Langer, R Komaki… - Journal of the …, 2011 - academic.oup.com
Background The combination of chemotherapy with thoracic radiotherapy (TRT) compared
with TRT alone has been shown to confer a survival advantage for good performance status …
with TRT alone has been shown to confer a survival advantage for good performance status …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
…, MA Gubens, M Hennon, L Horn, R Komaki… - Journal of the National …, 2017 - jnccn.org
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses
on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic …
on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic …
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line …
…, JA Karam, BD Kavanagh, C Tang, R Komaki… - The lancet …, 2016 - thelancet.com
Background Evidence from retrospective studies suggests that disease progression after first-line
chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …
chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …
Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology …
…, S Taylor IV, D Johnson, R Livingston, R Komaki… - Chest, 2000 - Elsevier
Study objectives The purpose of this phase III clinical trial was to test whether chemotherapy
followed by radiation therapy resulted in superior survival to either hyperfractionated …
followed by radiation therapy resulted in superior survival to either hyperfractionated …
Non–small cell lung cancer
…, DH Johnson, A Kessinger, R Komaki… - Journal of the national …, 2010 - jnccn.org
Lung cancer is the leading cause of cancer-related death in the United States. An estimated
219,440 new cases (116,090 men; 103,350 women) of lung and bronchus cancer were …
219,440 new cases (116,090 men; 103,350 women) of lung and bronchus cancer were …